Chimeric growth factor receptors

CrGFRs in lymphocytes allow in vivo expansion of T cells and NK cells without preconditioning and IL-2, addressing the limitations of ACT by reducing toxicity and hospitalization, thereby expanding the patient pool and lowering costs.

JP2024156656AInactive Publication Date: 2024-11-06INSTIL BIO UK LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024102884
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-06-21
Filing Date
2024-06-26
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current adoptive cell therapy (ACT) for cancer treatment requires harsh preconditioning treatments and high doses of interleukin-2 (IL-2), leading to patient immunocompromise, toxicity, and prolonged hospitalization, limiting its applicability to only a subset of patients.

Method used

Engineering lymphocytes, such as T cells and NK cells, with chimeric growth factor receptors (CrGFRs) that can be activated by a ligand like thrombopoietin or its agonists, allowing in vivo expansion without the need for extensive preconditioning and IL-2 support, using receptors like TpoR to induce proliferation and survival.

Benefits of technology

CrGFRs enable lymphocyte expansion in vivo with minimal toxicity to other cells, reducing the need for preconditioning and IL-2, thus shortening hospitalization, increasing the number of treatable patients, and lowering clinical costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156656000001_ABST
    Figure 2024156656000001_ABST
Patent Text Reader

Abstract

To provide T-cells and other lymphocytes engineered to express chimeric growth factor receptors, such as thrombopoietin fusion receptors, and also to provide the use of these cells in adoptive cell therapy.SOLUTION: Lymphocytes, including T cells and NK cells that contain a chimeric recombinant growth factor receptor (CrGFR) based on the thrombopoietin (Tpo) receptor, which can function as a growth switch, are produced through manipulation, which induces the proliferation of these modified lymphocytes following the binding of the CrGFR ligand to the receptor.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Adoptive cell therapy (ACT), which uses autologous T cells to mediate cancer regression, has shown great promise in early clinical trials. Several general approaches have been taken, such as the use of naturally occurring tumor-reactive or ex vivo expanded tumor-infiltrating lymphocytes (TILs). Furthermore, T cells can be genetically modified to retarget them towards a given tumor antigen. This can be performed by genetic transfer of peptide (p)-major histocompatibility complex (MHC)-specific T cell receptors (TCRs) or by synthetic fusions between tumor-specific single-chain antibody fragments (scFvs) and T cell signaling domains (e.g., CD3ζ), the latter termed chimeric antigen receptors (CARs). Transfer of TILs and TCRs has been found to be particularly successful when targeting melanoma (Rosenberg et al. 2011; Morgan 2006), while CAR therapy has shown great promise in the treatment of certain B cell malignancies (Grupp et al. 2013).

[0002] Current common treatment protocols for ACT entail administering an initial nonmyeloablative preconditioning treatment with cyclophosphamide and / or fludarabine, which removes most of the patient's circulating lymphocytes before reinfusing the ex vivo expanded cells. This allows room for new cells to grow and clears out the "cytokine sink" where normal cells compete for growth and survival signals with the newly infused cells. Along with the cells, patients receive cytokine support via infusion of high doses of interleukin (IL)-2, which promotes the engraftment and growth of the new cells. Currently, there are many factors that limit the technology of T cell ACT. The current preconditioning therapies mentioned above require hospitalization and may leave the patient immunocompromised. Furthermore, many patients are not healthy enough to tolerate the rigors of this treatment regimen. Even after preconditioning, the use of IL-2 as a supportive therapy is associated with the possibility of severe toxicity and intensive care procedures. Indeed, TIL therapy itself, unlike TCR and CAR therapy, is not associated with any significant on- or off-target toxicity, with most toxic events being related to the concomitant IL-2 infusion. Strategies that could minimize or reduce preconditioning and IL-2 supportive therapy would have significant benefits in: (i) shortening patient hospital stays; (ii) increasing the proportion of patients who could potentially be treated with ACT; and (iii) reducing the clinical costs associated with major hospitalizations, thereby making ACT more accessible to a larger number of patients. Therefore, there is a need for new ACT regimens that minimize the need for preconditioning treatment and / or IL-2 supportive therapy.

[0003] The present invention uses cells expressing recombinant chimeric growth factor receptors that can be turned on or off by administering a ligand of the CrGFR, which can be a clinically validated drug, allowing targeted cell proliferation in-vivo with minimal toxicity to other cells. Many reports have used the idea of ​​growth factor receptor engineering as a means to expand certain populations of cells or to develop selection methods for antibody engineering strategies. For example, numerous reports have demonstrated that antibody-TpoR or EpoR fusions can be used in many biotechnological strategies, such as single-chain antibody selection (Ueda et al. 2000, Kawahara et al. 2004), and many reports have demonstrated that growth factor receptor fusions can successfully expand the megakaryocytic cell line Ba / F3 and / or hematopoietic stem cells (Jin et al. 2000;Richard et al. 2000;Nagashima et al. 2003;Kawahara et al. 2011;Saka et al. 2013).

[0004] The thrombopoietin (Tpo) receptor (TpoR; CD110, c-mpl) is normally expressed in cells of the megakaryocytic lineage. In its normal state, TpoR is switched on in response to thrombopoietin, leading to megakaryocytopoiesis of platelets. There is also an active negative feedback loop that can use platelet expression of TpoR as a sink to reduce circulating levels of Tpo. Importantly, TpoR is not expressed in any other normal tissues or cancer cells (Columbyova 1995).

[0005] Recent reports have demonstrated that T cells can be engineered with wild-type TpoR and that T cell survival and proliferation can be controlled via administration of Tpo or Eltrombopag (Nishimura et al. 2018). However, there have been no reports of T cells and other lymphocytes being engineered to express chimeric growth factor receptors, such as thrombopoietin fusion receptors, and no reports of the use of these cells in ACT. [Brief description of the drawings]

[0006] [Figure 1]Schematic diagram of chimeric recombinant growth factor receptors containing growth factor domains. These receptors consist of the TpoR extracellular domain and a transmembrane domain spanning the plasma membrane. The intracellular domain consists of the TpoR cytoplasmic domain fused to one or more additional domains that increase the overall activity of the receptor and can be derived from a selection of growth factor domains, co-signaling domains, or co-stimulatory domains as detailed in the figure legend. Δ60 = TpoR with a 60 amino acid C-terminal deletion, IL2rβcyt = cytoplasmic domain of the IL2 receptor beta chain, SLAM = SLAM / CD150, TIAF1 = TGFβ1-inducible anti-apoptotic factor 1, TLR1 = Toll-like receptor 1, CD40 = CD40 / TNFRSF5, IL2rγ = IL-2 receptor common gamma chain, ITAM1 = immunoreceptor tyrosine-based activation motif from CD3ζ, LMP1 = Epstein-Barr virus latent membrane protein 1. [Diagram 2] Schematic diagram of chimeric recombinant growth factor receptors containing costimulatory domains. These receptors consist of the TpoR extracellular domain and a transmembrane domain spanning the plasma membrane. The intracellular domain consists of a costimulatory domain from a defined costimulatory receptor, such as, but not limited to, CD28 or CD137. [Diagram 3] 1 is a schematic diagram of the genetic organization of the lentiviral transgene. The TpoR transgene was codon optimized and cloned downstream of the EF1α promoter by paired XbaI and NheI restriction digestion of the pSF.Lenti lentiviral vector. [Figure 4] Figure 1 shows flow analysis of untransduced wild-type (WT) and variant chimeric recombinant growth factor receptors in JurkatE6.1 cells. Jurkat E6.1 T cells were transduced with lentiviral particles carrying the indicated transgenes. Expression was assessed 72 hours post-infection using anti-CD110-PE antibody. [Diagram 5]Figure 1 shows the analysis of chimeric recombinant growth factor receptor activity in Ba / F3 cells. The cytokine-dependent murine B cell line Ba / F3 was transduced with the indicated CrGFRs and incubated with either IL-3 or eltrombopag for 10 days. CrGFR expression was assessed by flow cytometry at the indicated time points using CD110 antibody. [Figure 6] Figure 13: Analysis of Eltrombopag and IL-2 on primary human T cells from donor 1. Primary human T cells from donor 1 were transduced with WT TpoR or variant CrGFR and incubated in the presence of IL2 or eltrombopag. Cells were harvested at time points up to 21 days and the percentage of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody and a MACSQuant analyzer. [Figure 7] Figure 13: Analysis of Eltrombopag and IL-2 on primary human T cells from donor 2. Primary human T cells from donor 2 were transduced with WT TpoR or variant CrGFR and incubated in the presence of IL2 or eltrombopag. Cells were harvested at time points up to 21 days and the percentage of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody and a MACSQuant analyzer. [Figure 8] Analysis of Eltrombopag and IL-2 on primary human T cells from donor 3. Primary human T cells from donor 3 were transduced with WT TpoR or variant CrGFR and incubated in the presence of IL2 or eltrombopag. Cells were harvested at time points up to 21 days and the percentage of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody and a MACSQuant analyzer. [Figure 9]Figure 1. Selection of optimal CrGFR for the next round of analysis. Flow cytometry plots showing expression of CrGFR in primary human T cells from three donors after 21 days of incubation with eltrombopag. The receptors TpoR.CD40, TpoR.IL2rγ, TpoR.ITAM1, TpoR.Δ60, TpoR.LMP1-cyto and TpoR.TpoR-cyto.LMP1-cyto were selected for further comparison with wt TpoR. [Figure 10] Analysis of Eltrombopag and IL-2 on CrGFR-sorted primary human T cells from donor 4. Primary human T cells from donor 4 were transduced with WT TpoR or variant CrGFR, selected for IL2 or eltrombopag, and enriched for expression by Miltenyi MACS technology incubated in the presence of IL2 or eltrombopag. Cells were removed at time points up to 7 days and the number of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody, DRAQ7 viability dye, and a MACSQuant analyzer. [Figure 11] Analysis of Eltrombopag and IL-2 on CrGFR-sorted primary human T cells from donor 5. Primary human T cells from donor 5 were transduced with WT TpoR or variant CrGFR, selected for IL2 or eltrombopag, and enriched for expression by Miltenyi MACS technology incubated in the presence of IL2 or eltrombopag. Cells were removed at time points up to 7 days and the number of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody, DRAQ7 viability dye, and a MACSQuant analyzer. [Figure 12]Analysis of Eltrombopag and IL-2 in CrGFR-sorted primary human T cells from donor 6. Primary human T cells from donor 6 were transduced with WT TpoR or variant CrGFR, selected for IL2 or eltrombopag, and enriched for expression by Miltenyi MACS technology incubated in the presence of IL2 or eltrombopag. Cells were removed at time points up to 7 days and the number of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody, DRAQ7 viability dye, and a MACSQuant analyzer. [Figure 13] Analysis of chimeric recombinant growth factor receptors in TIL042. Tumor infiltrating lymphocytes from TIL042 were transduced with WT TpoR or the indicated variant CrGFR and incubated with IL2, eltrombopag, IL-2 + eltrombopag, or no growth factors in the presence of patient-matched tumor lines. Cells were analyzed and counted on days 4 and 7 and the number of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody, DRAQ7 viability dye, and a MACSQuant analyzer. The graph shows counts from days 4 to 7 when recovery of TILs occurs after an initial decrease in numbers caused by tumor regulators and / or activation-induced cell death. [Figure 14] Analysis of chimeric recombinant growth factor receptors in ovarian TILs. Tumor-infiltrating lymphocytes from three ovarian TILs were transduced with WT TpoR or the indicated variant CrGFR and incubated with eltrombopag or without growth factors in the presence of patient-matched tumor cells. Cells were analyzed and counted on days 4 and 7, and the number of cells expressing the receptor was assessed using a PE-conjugated anti-CD110 antibody, DRAQ7 viability dye, and a MACSQuant analyzer. The graph shows counts from days 4 to 7, when recovery of TILs occurs after an initial decrease in numbers caused by tumor regulators and / or activation-induced cell death. [Figure 15]Figure 1 shows induction of pSTAT by chimeric recombinant growth factor receptors. Primary human T cells were isolated and transduced with the indicated CrGFR. Cells were enriched for CrGFR expression using Miltenyi MACS technology and expanded by polyclonal stimulation. Enriched cells were stimulated with either medium alone (RPMI), IL2, IL12, Tpo, or Eltrombopag (Elt) for 4 hours, followed by methanol fixation and intracellular staining with an antibody directed against phospho-STAT5. Summary of the Invention

[0007] The inventors have demonstrated that lymphocytes, including T cells and NK cells, can be engineered to contain CrGFRs that can function as a proliferation switch. This allows lymphocytes to proliferate in-vivo by administering CrGFR ligands to patients. The inventors have demonstrated that, for example, thrombopoietin (Tpo) receptor (TpoR; CD110, c-mpl)-based CrGFRs induce the proliferation of engineered lymphocytes after binding of CrGFR ligands to the receptor. Thus, the ligands provide protection from proliferation or activation-induced cell death of cells expressing CrGFRs, but are expected to be less toxic due to the lack or low expression of the receptor in other cells in the patient. CrGFRs based on TpoR or other related growth factor receptors could be valuable tools to increase lymphocyte proliferation in vitro and in vivo in adoptive cell therapy.

[0008] Thus, in a first aspect, the present invention provides a method for producing a medicament for the treatment of a pulmonary arthritis, comprising: (i) the extracellular (EC) domain; (ii) the thrombopoietin transmembrane (TM) domain; and (iii) a first intracellular (IC) domain, and optionally, (iv) a second intracellular domain The present invention provides a lymphocyte, including a T cell or a NK cell, that comprises a chimeric recombinant growth factor receptor (CrGFR) comprising the

[0009] CrGFRs are designed such that binding of a receptor ligand to the CrGFR results in receptor activation and the transmission of proliferative signals to cells, inducing proliferation and / or survival. The ligand can be human thrombopoietin, or a thrombopoietin receptor agonist, such as Eltrombopag, Lusotrombopag, Avatrombopag, or Romiplastim.

[0010] The EC domain may be a human c-mpl EC domain (which binds to human Tpo) or may be one or more of: i) a truncated EC domain, ii) a truncated c-mpl EC domain, iii) a selection marker, such as CD34. The IC domain of the CrGFR may include a JAK binding domain. The IC domain may consist of two or more growth factor receptor or other signaling domains, one of which may be from the list of human growth hormone receptor, human prolactin receptor, or human thrombopoietin receptor (c-mpl), and the additional growth factor or other signaling domain may be from the list of (but not limited to) cytokine receptor signaling domains (e.g., IL2 receptor), co-signaling domains (e.g., CD40), viral oncogenic proteins (e.g., LMP1), co-stimulatory domains (e.g., CD28, CD137, CD150, etc.), or other mitogenic domains (e.g., Toll-like receptors, immunoreceptor tyrosine-based activation motifs, CD3 signaling domain, etc.).

[0011] The lymphocytes may be tumor infiltrating lymphocytes (TILs), T cells, including regulatory T cells (Tregs) or primary T cells, or NK cells, or dendritic cells. In addition to the CrGFR, the lymphocytes, T cells or NK cells may contain a recombinant T cell receptor (TCR) or a chimeric antigen receptor (CAR).

[0012] In a second aspect, the present invention provides a nucleic acid sequence encoding a CrGFR. In a third aspect, the present invention provides a vector comprising a nucleic acid sequence according to the second aspect, and, if present, comprising a TCR and / or a CAR nucleic acid sequence. In a fourth aspect, the present invention provides a method for producing a lymphocyte, or a T cell or an NK cell, as described in the first aspect of the invention, comprising the step of introducing a nucleic acid or vector encoding a CrGFR into a lymphocyte. In a fifth aspect, the present invention provides a pharmaceutical composition comprising a vector according to the third aspect, or a lymphocyte (including a T cell or a NK cell) according to the first aspect, together with a pharma- ceutically acceptable carrier, diluent or excipient. In a sixth aspect, the present invention provides a method of in-vivo cell expansion comprising administering to a subject lymphocytes, or T cells or NK cells, of the first aspect, or the pharmaceutical composition of the fifth aspect. The cells may be expanded in-vivo by administering to the subject thrombopoietin, or a thrombopoietin agonist, such as eltrombopag. In a seventh aspect, the present invention provides a lymphocyte, including a T cell or an NK cell, according to the first aspect, or a vector according to the third aspect, for use in adoptive cell therapy. In an eighth aspect, the present invention provides a lymphocyte, including a T cell or an NK cell, according to the first aspect, or a vector according to the third aspect, for use in a method of treating cancer. In a ninth aspect, the present invention provides the use of a lymphocyte according to the first aspect, or a vector according to the third aspect, in the manufacture of a medicament for treating cancer. In a tenth aspect, the present invention provides eltrombopag or Tpo for use in adoptive cell therapy. In an eleventh aspect, the present invention provides eltrombopag or Tpo for use in the in vivo expansion of lymphocytes, including T cells or NK cells. In a twelfth aspect, the present invention provides a lymphocyte of the first aspect for use in combination with thrombopoietin or a thrombopoietin receptor agonist, such as eltrombopag, in the treatment of cancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Chimeric recombinant growth factor receptor (CrGFR) Provided herein is a recombinant growth factor receptor (CrGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin transmembrane (TM) domain; and (iii) a chimeric growth factor receptor intracellular (IC) domain. In a simple form, the CrGFR may comprise a full-length human Tpo receptor (as depicted in FIG. 1 herein) or a derivative or variant thereof that maintains signal transduction and cell proliferation in response to ligand binding (e.g., it may comprise a truncated thrombopoietin signaling domain that has been shown to maintain signal transduction capability). The CrGFR may be in a modular form with EC, TM and IC domains from different receptors. However, the CrGFR must maintain its ability to transmit growth signals to cells upon ligand binding. The CrGFR may be activated and transmit growth signals to cells upon ligand binding to the TM domain. The signaling domain may comprise one or more additional signaling domains.

[0014] Suitable CrGFRs can be selected based on GFRs that have restricted expression in normal human tissues, such as GFRs that are expressed only in a small cell population or that are restricted to a particular cell type, such as c-kit. Alternatively, the natural ligand binding domain of the growth factor receptor can be removed and replaced, for example, with a marker or other EC domain. CrGFR can contain an EC domain (e.g., a truncated version of the TpoR EC domain) and / or a marker (e.g., CD34) that does not have growth factor binding function, as well as the TM and IC domains from TpoR. The proliferation of cells with this type of receptor can then be stimulated by binding of eltrombopag to the TM domain. The CrGFR may be expressed alone under the control of a promoter in a therapeutic population of cells having therapeutic activity, such as tumor infiltrating lymphocytes (TILs).

[0015] Alternatively, the CrGFR can be expressed together with a therapeutic transgene, such as a chimeric antigen receptor (CAR) and / or a T cell receptor (TCR), as illustrated, for example, in Figure 14. Suitable TCRs and CARs can be found in the literature, for example, in the HLA-A * 02-NYESO-1 specific TCR (Rapoport et al. Nat Med 2015) or anti-CD19scFv.CD3ζ fusion CAR (Kochenderfer et al. J Clin Oncol 2015) are well known and have been successfully used to treat myeloma or B-cell malignancies, respectively. The CrGFR described herein can be expressed with any known CAR or TCR, thus providing cells with a controllable proliferation switch that allows cell proliferation / survival in-vitro or in-vivo, and a conventional activation mechanism in the form of a TCR or CAR for anti-cancer activity. Thus, the present invention provides cells for use in adoptive cell therapy that include the CrGFR described herein and a TCR and / or CAR that specifically binds to a tumor-associated antigen.

[0016] The CrGFR can have the TM domain and the first IC domain of the human Tpo receptor, and a wild-type or truncated Tpo receptor EC domain (without native ligand binding function). Particular embodiments of the CrGFR include those shown in FIG. 1 and FIG. In some embodiments, the growth factor receptor (CrGFR) is constructed based on the TpoR receptor, with at least the TM and IC regions (see SEQ ID NO: 1, showing the TpoR TM domain and 514-635 and the TpoR cytoplasmic domain) retained, and with an additional (second) IC domain added to the construct to enhance signaling in response to Tpo or Tpo agonist binding. Thus, in some embodiments, the CrGFR comprises: (i) the TpoR extracellular (EC) domain, or a truncated TpoR EC domain; (ii) the thrombopoietin transmembrane (TM) domain; (iii) a first intracellular (IC) domain comprising the human thrombopoietin IC domain (or a truncated version thereof, e.g., delta 60); and (iv) a second intracellular domain selected from a costimulatory receptor, a cytokine receptor, a co-signaling receptor, or an IC domain from the human thrombopoietin receptor (c-mpl). For example, the second IC domain can be an IC domain from CD40, IL2R (IL2rβ, IL2Rγ), ITAM1 or LMP1.

[0017] In some embodiments, the CrGFR comprises i) an EC domain; a TM domain and an IC domain as set forth in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, or a variant thereof having at least 80%, 85%, 90%, 95% 97% or 99% sequence identity. Suitable EC domains include those described herein, e.g., truncated TpoR EC domains. These receptors retain the ability to bind human thrombopoietin or thrombopoietin receptor agonists. In other embodiments, the IC domain of wt Tpo is replaced with the IC domain from a suitable receptor, e.g., LMP1, IL2R, CD28, CD137; examples of such constructs are shown in Figure 1 as "TpoR.LMP1" and "TpoR.IL2rβ-cyt.TpoR-cyt" and in Figure 2 as "TpoRec.TpoRtm CD28cyto" and "TpoRec.TpoRtm CD137cyto."

[0018] EC Domain The EC domain can be an EC domain from TpoR (SEQ ID NO:1), or a derivative or variant thereof that maintains signal transduction and cell proliferation in response to ligand binding to the receptor. For example, when a TM domain that can cause receptor activation upon ligand binding is used, such as the TpoR TM domain, the EC domain may not be required for CrGFR signal transduction.The EC domain may then be a truncated or mutated native domain (e.g., without ligand binding function), such as a truncated TpoR EC domain.The native EC domain can be replaced with a marker for selection and / or in vivo monitoring, such as a truncated CD34.

[0019] TM Domain The TM domain from the Tpo receptor (TpoR) (shown in FIG. 1) can be used, including derivatives or variants thereof that maintain signaling and cell proliferation in response to ligand binding to the receptor. This may be useful since TpoR is known to have restricted expression in normal human tissues and is also known to bind eltrombopag, lusutrombopag, and avatrombopag, and thus CrGFRs containing the TM domain from the Tpo receptor can be activated by exposing the cells in vitro or in vivo to clinically validated compounds with known toxicity profiles.

[0020] IC Domain The growth factor receptor intracellular (IC) domain from the Tpo receptor (shown in SEQ ID NO:1) can be used, including derivatives or variants thereof (e.g., a truncated TpoR signaling domain as shown in SEQ ID NO:2) that maintain signaling and cell proliferation in response to ligand binding to the receptor. This can be combined with the TM domain from the Tpo receptor to achieve good levels of cell proliferation in response to ligand binding. Other growth factor receptor-like IC domains may be suitable for use in constructing the CrGFR of the present invention, since these receptors are known to activate the same cell signaling pathway as Tpo receptor. For example, IC domains from G-CSF, GM-CSF, prolactin or human growth hormone can be used to construct CrGFR when combined with TpoR TM domain. The ability of CrGFRs containing these IC domains to induce cell proliferation in response to receptor agonists, such as eltrombopag, can then be determined using the methods described in the Examples herein. The IC domain of TpoR can be truncated up to 79 amino acids at the C-terminus. Truncation beyond this has been shown to completely knock out TpoR activity (Gurney et al. PNAS 1995). Additionally, the IC domain may also comprise a second domain derived from one of the following (without limitation): a cytokine receptor signaling domain (e.g., IL2 receptor), a co-signaling domain (e.g., CD40), a viral oncogenic protein (e.g., LMP1), a co-stimulatory domain (e.g., CD28, CD137, CD150, etc.) or other mitogenic domain (e.g., Toll-like receptors, immunoreceptor tyrosine-based activation motifs, CD3 signaling domain, etc.).

[0021] Cytokine receptors are a widespread group of receptors expressed on many cell types and are involved in sensing cues in the extracellular environment by binding to soluble cytokines. This binding event triggers a signaling cascade via JAK / STAT signaling, resulting in the upregulation of genes involved in survival and proliferation. Such receptors include the IL-2 receptor, IL-4 receptor, and thrombopoietin receptor (Liongue et al. 2016). Costimulatory receptors are proteins involved in enhancing the activity of T cells when the cell receives a primary signal by the T cell receptor. It is based on the concept of signal 1 and signal 2, whereby signal 1 is delivered via binding of the T cell receptor to peptide-MHC and signal 2 is delivered via binding of the T cell's costimulatory receptor to a costimulatory ligand on the target cell (e.g., dendritic cell). Signal 2, delivered via the costimulatory domain, provides the T cell with a critical survival signal. Common costimulatory receptors include CD28, CD137, and CD150 (Leitner et al. 2010). The term costimulatory signaling defines a group of cell membrane proteins that provide supportive signals similar to those described for costimulatory receptors, but under certain circumstances may not be considered to be costimulatory since they may not be expressed in T cells, such receptors include CD40, which is normally expressed on antigen-presenting cells and enhances survival upon binding of CD40-ligand expressed on T cells (He et al. 2012; Kumar et al. 2018).

[0022] This second IC domain can be fused directly to the C-terminus of the first IC domain (e.g., the TpoR IC domain located next to the transmembrane Tpo domain) or can be fused via a linker domain. Thus, a chimeric growth factor receptor can include the TpoR transmembrane domain and the TpoR IC domain (first IC domain), and a second IC domain that can be derived from TpoR or can be a cytokine receptor signaling domain, a co-signaling domain, a viral oncogenic protein (e.g., LMP1) or a co-stimulatory domain as described in the previous paragraph. Additionally, costimulatory, co-inhibitory, or co-signaling domains can be fused directly to the TpoR transmembrane domain to generate receptors such as those shown in Figure 2 and SEQ ID NOs: 13 and 14. These receptors may also include an additional (second) IC domain, such as a TpoR domain.

[0023] cell The cells used in the present invention may be any lymphocyte useful in adoptive cell therapy, such as T cells or natural killer (NK) cells, NKT cells, gamma / delta T cells or regulatory T cells, etc. The cells may be allogeneic or autologous cells. T cells or T lymphocytes are a type of lymphocyte that play a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T cell receptor (TCR) on the cell surface. There are different types of T cells, as summarized below.

[0024] Cytotoxic T cells (TC cells, or CTLs) destroy virus-infected and tumor cells and are also involved in transplant rejection. CTLs express CD8 molecules on their surface. These cells recognize their targets by binding to antigens associated with MHC class I, which are present on the surface of all nucleated cells. Through IL-10, adenosine and other molecules secreted by regulatory T cells, CD8+ cells can be inactivated into an anergic state, which prevents autoimmune diseases such as experimental autoimmune encephalomyelitis. Memory T cells are a subset of antigen-specific T cells that persist for long periods after an infection has cleared. They provide the immune system with a "memory" of past infections by rapidly expanding large numbers of effector T cells upon re-exposure to cognate antigen. Memory T cells include three subtypes: central memory T cells (TCM cells) and two types of effector memory T cells (TEM cells and TEMRA cells). Memory cells can be either CD4+ or CD8+. Memory T cells typically express the cell surface protein CD45RO. Regulatory T cells (Treg cells), previously known as suppressor T cells, are important for the maintenance of immune tolerance. Their primary role is to shut down T cell-mediated immunity towards the end of an immune response and to suppress autoreactive T cells that have escaped the process of negative selection in the thymus.

[0025] Two major classes of CD4+ Treg cells have been described: naturally occurring Treg cells and adaptive Treg cells. Naturally occurring Treg cells (also known as CD4+CD25+FoxP3+ Treg cells) arise in the thymus and have been associated with interactions between both TSLP-activated myeloid (CD11c+) and plasmacytoid (CD123+) dendritic cells and developing T cells. Naturally occurring Treg cells can be distinguished from other T cells by the presence of an intracellular molecule called FoxP3. Adaptive Treg cells (also known as Tr1 or Th3 cells) can arise during normal immune responses.

[0026] Natural killer cells (or NK cells) are a type of cytotoxic cell that forms part of the innate immune system. NK cells provide a rapid response to innate signals from virus-infected cells in an MHC-independent manner. NK cells (belonging to the group of innate lymphoid cells) are defined as large granular lymphocytes (LGL) and constitute the third type of cell differentiated from common lymphoid precursors that give rise to B and T lymphocytes.

[0027] nucleic acid One aspect of the invention provides a nucleic acid sequence of the invention encoding any of the CrGFRs, polypeptides, or proteins (including functional portions and functional variants thereof) described herein. As used herein, the terms "polynucleotide," "nucleotide," and "nucleic acid" are intended to be synonymous with each other. Those skilled in the art will understand that, as a result of the degeneracy of the genetic code, many different polynucleotides and nucleic acids can code for the same polypeptide. It will be further understood that those skilled in the art can use routine techniques to make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described herein to reflect the codon usage of any particular host organism in which the polypeptide is to be expressed.

[0028] Nucleic acids according to the present invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides that contain synthetic or modified nucleotides therein. Many different types of modifications to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, the addition of acridine or polylysine chains at the 3' and / or 5' ends of the molecule. For the purposes of the present invention, it is understood that polynucleotides may be modified by any method available in the art. Such modifications may be performed to enhance the in vivo activity or life span of the polynucleotide of interest. The terms "variant," "homolog" or "derivative" in relation to a nucleotide sequence include any substitution, alteration, modification, replacement, deletion or addition of one or more nucleic acid(s) from or to the sequence.

[0029] The nucleic acid sequence may encode the protein sequences set forth in SEQ ID NOs: 3-14 or variants thereof, including nucleic acid sequences that encode or contain truncated forms of the Tpo Receptor as set forth in SEQ ID NO:2. The nucleotide sequence may include the nucleotide sequence of TpoR shown in SEQ ID NOs: 17 to 28, or a variant thereof. The present invention also provides a nucleic acid sequence comprising a nucleic acid sequence encoding a CrGFR and a further nucleic acid sequence encoding a T cell receptor (TCR) and / or a chimeric antigen receptor (CAR). The nucleic acid sequence can be linked by a sequence that allows two or more nucleic acid sequences to be co-expressed.For example, the construct can include an internal promoter, an internal ribosome entry sequence (IRES), or a sequence that codes for a cleavage site.The cleavage site can be self-cleaving, so that when the polypeptide is produced, it is immediately cleaved into individual proteins without the need for any external cleavage activity. A variety of autocleavage sites are known, including the foot and mouth disease virus (FMDV) and the 2a autocleavage peptide. The co-expression sequence may be an internal ribosome entry sequence (IRES). The co-expression sequence may be an internal promoter.

[0030] vector In one aspect, the invention provides a vector comprising a nucleic acid sequence or a nucleic acid construct of the invention. Such vectors can be used to introduce nucleic acid sequences or nucleic acid constructs into a host cell, so that it expresses one or more CrGFRs according to the first aspect of the invention, and optionally one or more other proteins of interest (POIs), such as a TCR or a CAR. Vector can be, for example, plasmid or viral vector, for example retrovirus vector or lentivirus vector, or transposon-based vector or synthetic mRNA.Retrovirus, for example lentivirus-derived vector, allows long-term stable integration of one or more transgenes and their propagation in daughter cells, so it is a suitable tool to achieve long-term gene transfer. The vector is capable of transfecting or transducing lymphocytes, including T cells or NK cells. The present invention also provides a vector into which the nucleic acid of the present invention is inserted. Expression of natural or synthetic nucleic acids encoding CrGFR and optionally TCR or CAR is typically achieved by operably linking the nucleic acids encoding CrGFR and TCR / CAR polypeptides or portions thereof to one or more promoters and incorporating the construct into an expression vector. The vector may be suitable for replication and integration in eukaryotic cells. Typical cloning vectors include transcription and translation terminators, initiation sequences, and promoters useful for regulating the expression of the desired nucleic acid sequence. Viral vector technology is well known in the art and described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals, see also WO 01 / 96584; WO 01 / 29058; and U.S. Patent No. 6,326,193.

[0031] In some embodiments, the nucleic acid construct is as shown in the figures herein. In some embodiments, the nucleic acid is a multicistronic construct that allows expression of multiple transgenes (such as CrGFR and TCR and / or CAR) under the control of a single promoter. In some embodiments, the transgenes (such as CrGFR and TCR and / or CAR) are separated by a self-cleaving 2A peptide. Examples of 2A peptides useful in the nucleic acid construct of the present invention include F2A, P2A, T2A and E2A. In other embodiments, the nucleic acid construct of the present invention is a multicistronic construct that includes two promoters; one promoter driving the expression of CrGFR and another promoter driving the expression of TCR or CAR. In some embodiments, the dual promoter construct of the present invention is unidirectional. In other embodiments, the dual promoter construct of the present invention is bidirectional. To assess expression of a CrGFR polypeptide or a portion thereof, the expression vector introduced into the cells may also contain either a selectable marker gene or a reporter gene, or both, to facilitate identification and selection of expressing cells from a population of cells that are desired to be transfected or transduced via a viral vector. The CrGFR polypeptide may incorporate a marker, such as CD34, as part of the EC domain.

[0032] Pharmaceutical Compositions The present invention also relates to pharmaceutical compositions comprising the vectors or CrGFR expressing cells of the invention together with a pharma- ceutically acceptable carrier, diluent or excipient, and optionally one or more additional pharma- ceutically active polypeptides and / or compounds. Such formulations may be, for example, in a form suitable for intravenous infusion.

[0033] Treatment method The cells expressing CrGFR for use in the methods of the present invention, including T cells and NK cells, can be generated ex vivo from the patient's own peripheral blood (autologous), or in the setting of hematopoietic stem cell transplantation from donor peripheral blood or peripheral blood from an unrelated donor (allogeneic). Alternatively, T cells or NK cells can be derived from ex vivo differentiation of inducible progenitor cells or embryonic progenitor cells into T cells or NK cells. In these cases, T cells expressing CrGFR and optionally CAR and / or TCR are generated by introducing DNA or RNA encoding CrGFR and optionally CAR and / or TCR by one of a number of means, including transduction by viral vector, transfection by DNA or RNA. The T cells or NK cells expressing the CrGFR and optionally the TCR and / or CAR of the present invention can be used in the treatment of hematological cancers or solid tumors.

[0034] The method of treating disease relates to the therapeutic use of the vector of the present invention or the cell comprising T cell or NK cell.In this regard, the vector, or the T cell or NK cell can be administered to a subject with an existing disease or condition to alleviate, reduce or improve at least one symptom associated with the disease, and / or to slow down, reduce or prevent the progression of the disease.The method of the present invention can cause or promote T cell-mediated cancer cell death. The vector, or T cells or NK cells according to the present invention can be administered to a patient together with one or more additional therapeutic agents. One or more additional therapeutic agents can be co-administered to a patient. By "co-administering" is meant administering one or more additional therapeutic agents and the vector, or T cells or NK cells of the present invention close enough in time to allow the vector, or T cells or NK cells to enhance the effect of the one or more additional therapeutic agents, or vice versa. In this regard, the vector or cells can be administered first, and then the one or more additional therapeutic agents, or vice versa. Alternatively, the vector or cells and the one or more additional therapeutic agents can be administered simultaneously. Suitable therapeutic agents that can be co-administered with the vector or cells of the present invention include any growth factor receptor agonist that activates CrGFR, such as eltrombopag (rINN, code name SB-497115-GR), lusutrombopag and avatrombopag or romiplostim.

[0035] Eltrombopag may be particularly useful in the methods of the present invention because of its known toxicity profile. Preclinical studies have shown that this compound selectively interacts with the thrombopoietin receptor, leading to activation of the JAK-STAT signaling pathway and increased proliferation and differentiation of megakaryocytes. Animal studies have confirmed that administration can increase platelet counts. In 73 healthy volunteers, high doses of eltrombopag significantly increased the number of circulating platelets and were well tolerated. See, for example, Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (Jun 2007). "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist". Blood 109 (11): 4739-41. Thus, in the methods of the present invention, the appropriate dose of eltrombopag can be determined based on the clinical studies already disclosed and the in-vitro assays described herein.

[0036] Another potentially useful agent is IL-2, which is currently used in existing cell therapies to increase the activity of administered cells. However, as mentioned above, IL-2 treatment is associated with toxicity and tolerance issues. Therefore, the object of the present invention is to reduce the amount of IL-2 that needs to be administered (e.g., to low toxic levels) or eliminate the need for IL-2 administration by stimulating cell proliferation using an agonist that binds to CrGFR. For purposes of the methods of the invention in which cells are administered to a patient, the cells can be allogeneic or autologous to the patient.

[0037] Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure. All documents mentioned herein are incorporated by reference in their entirety. As used herein, "and / or" is to be understood as the specific disclosure of each of the two specified features or components, with or without the other. For example, "A and / or B" is to be understood as the specific disclosure of (i) A, (ii) B, and (iii) each of A and B, as if each were individually set forth herein. Unless the context dictates otherwise, the above feature descriptions and definitions are not limited to any particular aspect or embodiment of the invention, but apply equally to all aspects and embodiments described. Certain aspects and embodiments of the present invention will now be described, by way of example, and with reference to the figures above and tables below. EXAMPLES

[0038] Example 1 Generation and evaluation of CrGFR-expressing T cells material and method Plasmids The pSF.Lenti.EF1α plasmid was generated by Oxford Genetics by replacing the existing CMV promoter in pSF.Lenti.CMV.PGK.puro with the elongation factor (EF) 1α promoter to generate pSF.Lenti.EF1α.PGK.puro. The PGK.Puro segment was then removed and the TpoR construct was cloned by XbaI / NheI digestion at the NheI site downstream of the puromycin resistance gene. Packaging plasmids pVSVg, pCgpV and pRSV.Rev (ViraSafe Lentiviral Packaging System-Pantropic) were obtained from Cell Biolabs (VPK-206).

[0039] reagent The following reagents were supplied by the following manufacturers:- Abcam - DRAQ7 (AB109202-1ml) Miltenyi Biotec - Anti-Melanoma (MCSP)-PE (130-099-413); Anti-CD34-APC (130-090-954), Anti-CD45-FITC (130-080-202), Anti-CD71-APC (130-099-239), Anti-CD110-PE BD Biosciences - Anti-CD34-PE (555822); E-Biosciences - Fixable Viability dye eFlor 450 (65-0863-18), Fixable Viability dye eFlor 780 (65-0865-18).

[0040] cell line Jurkat E6.1 and Ba / F3 cell lines were cultured in RPMI (T cell medium: TCM) supplemented with 10% FCS (F9665-500ml: Sigma), 1% 1M HEPES (H0887-100ml) and 1% penicillin / streptomycin (P0781-100ml). Cell line 293T was routinely cultured in DMEM supplemented with 10% FCS and 1% penicillin / streptomycin (P0781-100ml) (D10).

[0041] Isolation of T cells T cells were isolated from PBMCs from buffy coats. Briefly, buffy coats were obtained from NHSBT and PBMCs were isolated by density centrifugation over Ficoll. Untouched T cells were isolated using paramagnetic beads (see below). T cells were cultured in RPMI (T cell medium: TCM) supplemented with 10% FCS (F9665-500ml: Sigma), 1% of 1M HEPES (H0887-100ml) and 1% penicillin / streptomycin (P0781-100ml).

[0042] Production of lentivirus 6×10 6293T cells were seeded in 10 ml of D10 in poly-d-lysine coated T75 flasks (Greiner) the day before transfection. On the day of transfection, 0.025 M HEPES buffered serum free DMEM (pH 7.1) and 0.025 M HEPES buffered D10 (pH 7.9) were prepared. A 1.5 ml transfection mix was made with 10 μg of lentiviral transfer plasmid (pSF.Lenti) and 10 μg each of pVSVg, pCgpV and pRSV.Rev and CaCl2 per flask, adjusted to a final concentration of 0.05 M with pH 7.1 medium. Transfection complexes were allowed to form for 30 min and then added dropwise to the flask containing 6 ml of pH 7.9 medium. After 24 h, the medium was replaced with 10 ml of fresh D10. After 24 and 48 hours, the media was collected, combined, and concentrated using a Lenti-X concentrator (Clontech-Takara: 631232). The concentrated lentiviral particles were resuspended in 10 times the original supernatant volume and stored at -80°C until use.

[0043] T cell transduction 1×10 5 T cells were added per well of a flat-bottom 96-well plate. Plates were centrifuged and the supernatant aspirated before adding 50-100 μl of lentiviral supernatant supplemented with 4 μg / ml polybrene (hexadimethrine bromide - Sigma: H9268-5G) and IL-2 at the indicated concentrations. In some cases, the following activation reagents were added: Dynabeads™ Human T-Activator CD3 / CD28 (Thermo Fisher: 11131 D), Dynabeads™ Human T-Activator CD3 / CD28 / CD137 (Thermo Fisher 11162D) at the manufacturer's recommended concentrations.

[0044] Paramagnetic bead selection Paramagnetic bead sorting was performed using either anti-PE microbeads (Miltenyi Biotec or StemCell Technologies) or T cell isolation beads (17951: StemCell Technologies) according to the manufacturer's instructions.

[0045] Rapid Propagation Protocol (REP) T cells were expanded using irradiated buffy coat feeders. Briefly, 10 irradiated buffy coats were obtained from NHSBT and PBMCs were isolated by density centrifugation over Ficoll, combined and then cryopreserved. Thawed buffy coat feeders were mixed with T cells at a ratio of 1:20 to 1:100, with a final cell concentration of 1 × 10 in TCM + 200 lU / ml IL-2 and 1 μg / ml phytohemagglutinin in a T25 culture flask. 6 The upright flasks were placed at a 45° angle for the first 5 days, after which the flasks were returned to an upright position and the medium was replaced with a half-medium exchange. Medium exchanges were performed every 2-3 days for 14 days with fresh IL-2 to a final concentration of 200 lU / ml, after which the cells were either cryopreserved or directly assayed.

[0046] Design of the structure Already, we have verified that TpoR can be active in primary human T cells. However, attempts to modify the receptor have not always been straightforward. For example, a fusion between the TpoR Ec domain and the GCSF IC domain failed to express on the cell surface. Furthermore, prolactin receptor fusions did not appear to be completely surface stable. Furthermore, we reasoned that we could improve the signaling capacity of TpoR-based receptors in T cells by including signaling components that are likely to drive IL-2-like signals in engineered cells by activating JAK3, a signaling molecule involved in IL-2 signaling but not TpoR signaling. Therefore, we aimed to generate fusion receptors in which additional domains were fused directly to the C-terminus of the TpoR IC domain. We first generated fusions between TpoR and IL2rβ signaling domains. Previous attempts to generate fusions between TpoR and IL2rβ by completely removing the TpoR intracellular domain resulted in receptors that were not well expressed enough. Therefore, we took an alternative approach by fusing the Il2rβ signaling region to the N- or C-terminus of the TpoR signaling domain by creating a hybrid TpoR-IL2rβ signaling domain. We then generated receptors in which the cytoplasmic domains of TIAF1, TLR1, CD150, IL2rγ, CD40, LMP1 and ITAM1 from CD3ζ were fused to the TpoR signaling domain at the C-terminus. The reasons for choosing these receptors were as follows: TIAF1 - there is evidence that TIAF1 binds to JAK3 (Ji et al. 2000); TLR1 / CD40 - it has been shown that synergy between TLR and CD40 induces T cell proliferation (Ahonen et al. 2004) and furthermore that CD40 binds to JAK3 and requires JAK3 for signaling in B cells (Hanissian & Geha 1997); CD150 - there is evidence that CD150 can protect T cells from IL-2 deprivation (Aversa et al. 1997); ITAM1 - we decided to fuse a single ITAM from CD3ζ to the C-terminus of TpoR to induce a mitogenic response; LMP1 - LMP1 from the EBV virus has been shown to interact with JAK3 (Gires et al. 1997). (1999), and furthermore, we also fused LMP1 directly to the TpoR transmembrane domain because we thought that the TpoR cytoplasmic domain fusions might be too large and not well expressed. We also generated a CrGFR consisting of the TpoR extracellular and transmembrane domains fused to the cytoplasmic domains of CD28 and CD137 because we thought that a costimulatory growth signal could be provided upon administration of eltrombopag.The sequences of these constructs are shown below.

[0047] Constructs were cloned into pSF.Lenti (Oxford Genetics) via the XbaI and NheI sites. All fragments and constructs were codon optimized, gene synthesized and cloned by Genewiz.

[0048] Lentivirus production - Lentivirus production was performed using a triple plasmid packaging system (Cell Biolabs, San Diego, USA) by mixing 10 μg of each plasmid and 10 μg of the transgene-containing pSF.lentivirus plasmid together in serum-free RPMI containing 50 mM CaCl2. This mixture was added dropwise to a 50% confluent monolayer of 293T cells in a 75 cm2 flask. Viral supernatants were collected 48 and 72 hours after transfection, pooled, and concentrated using LentiPac Lentivirus Supernatant Concentrator (GeneCopoeia, Rockville, MD, USA) solution according to the manufacturer's instructions. Lentivirus supernatants were concentrated 10-fold and used to directly infect primary human T cells in the presence of 4 μg / ml polybrene (Sigma-Aldrich, Dorset, UK).

[0049] Peripheral blood mononuclear cells were isolated from normal healthy donors and activated with T cell activation proliferation beads (Invitrogen) for 24 h according to the manufacturer's instructions before addition of lentiviral supernatant. After expansion, cells were washed extensively to remove exogenous IL2 and plated in 96-well U-bottom plates. Cells were supplemented with IL2 (Proleukin) or eltrombopag (Stratech Scientific, Suffolk, UK). At various subsequent time points, cells were either stained with eFlor-450 fixable viability dye (eBioscience, UK) at a 1:400 dilution and counted directly from the wells using a MACSQuant hemocytometer, or stained with DRAQ7 viability dye and phycoerythrin-conjugated anti-CD110 antibody (Miltenyi Biotec, UK) and analyzed using a MACSQuant hemocytometer. Cell viability and / or transduction levels were then analyzed using MACSQuantify software (Miltenyi Biotec, UK).

[0050] result We first tested the functionality and expression profile of CrGFR in comparison with the wt receptor in JurkatE6.1 and Ba / F3 cells, a human T cell lymphoma and an IL-3-dependent murine B cell line, respectively. Although Ba / F3 are neither human nor T cells, they at least indicate whether the receptors can be properly folded and expressed and whether they can transmit signals. Lentiviral particles were generated and used to directly infect JurkatE6.1 and Ba / F3 cells. Jurkat cells were analyzed after 48 hours for expression by using a PE-conjugated anti-CD110 antibody. Ba / F3 cells were incubated with eltrombopag or murine IL-3, and expression of CrGFR was assessed over several days by analysis of CD110 expression by flow cytometry. As shown in Figure 4, all receptors were well detected in JurkatE6.1 cells, but three receptors (TpoR.SLAM, TpoR.TIAF1, and TpoR.IL2rβ-cyt.TpoR-cyt) had low expression profiles suggesting that they were not particularly well expressed on the surface. In Ba / F3 cells, all receptors were expressed and could be enriched in the population by adding eltrombopag, but IL-3 could not be enriched as expected (Figure 5). However, for the two IL2rβ fusion receptors, although they could be enriched in the population, the poor survival profile in Ba / F3 and the lack of live cells meant that the assay had to be rounded down for these receptors.

[0051] Next, we took these receptors and expressed them in primary human T cells and exposed these cells to IL-2 or eltrombopag. Primary human T cell populations from three donors were isolated from buffy coats and transduced with the indicated lentiviral constructs in the presence of CD3 / CD28 Dynabeads. After expansion, the cells were incubated with IL-2 or eltrombopag. The results are shown in Figures 6, 7, 8 (three donors). We saw increased T cell proliferation / survival with some receptors from some donors. We analyzed this entire data set by looking at the percentage of cells that showed a good percentage of viable cells in separate populations of CD110+ cells after 21 days. This further narrowed our receptor panel for further analysis to: TpoR.CD40, TpOR.IL2rγ, TpoR.ITAM1, TpOR.LMP1-cyt, and TpoR.TpoR-cyt-LMP1-cyt. TpoR.A60 also looked good, but this was not initially explored with the idea that it could be later incorporated into later generation fusion receptors.

[0052] We then repeated the experiment, using the receptors identified in the first round of selection to sort CrGFR+ cells using CD110+ selection with paramagnetic bead selection (Figures 10, 11 and 12). We observed enhanced survival of T cells engrafted with multiple CrGFR in all three donors. Notably, we confirmed proliferation of WT-TpoR, TpOR.CD40, TpOR.IL2rγ and TpoR.LMP1-cyto cells in the second donor (Figure 12) over media alone.

[0053] Next, we evaluated the ability of these receptors to promote survival / proliferation in a model of adoptive cell therapy by manipulating tumor-infiltrating lymphocytes. TILs from patient TIL042 (uveal black melanoma) were engineered with variant or wt CrGFR and mixed with patient-matched tumor cells (CTUM42.1). On days 4 and 7, total cells as well as CD110+ cells were counted. We confirmed an initial decrease in cell numbers, likely caused by AICD or endogenous suppressors. However, between days 4 and 7, we observed an increase in the number of CD110+ cells in all receptors tested with eltrombopag or eltrombopag + low-dose IL-2. Notably, the effect of TpoR.CD40 was promising, as there was no nonspecific enrichment with IL2 alone, and this effect was shown in other receptors tested.

[0054] We further evaluated the effect of CrGFR in ovarian TILs. Three ovarian TIL populations were engineered to express either WT or TpoR.CD40, TpoR.IL2rγ or TpoR.LMP1-Cyt variant receptors and mixed with patient-matched tumor cells in the presence or absence of eltrombopag. Total cells and CD110+ cells were counted after 4 and 7 days. We observed specific proliferation of CrGFR+ cells in the presence of tumor from days 4 to 7 in donor 2 and donor 3 for all receptors except TpOR.LMP1.cyt. In donor 1, there was no non-specific proliferation of CrGFR+ cells, but we confirmed that the addition of eltrombopag appeared to protect the cells from AICD (activation-induced cell death). Importantly, we confirmed that the activity of the TpoR.IL2rγ and TpoR.CD40 variants was superior to that of the WT receptor in all three donors (FIG. 13).

[0055] Finally, we verified the signaling potential of the novel CrGFR by performing phospho-STAT analysis upon treatment of CrGFR-expressing T cells with medium, cytokines, or drugs. For this purpose, T cells from four donors were transduced with either wt TpoR, TpoR.CD40, or TpoR.IL2rγ, enriched for CrGFR expression using a paramagnetic bead selection protocol, and then expanded using polyclonal stimulation. Cells were treated with medium alone (RPMI), IL-2, Tpo, or Eltrombopag (Elt) for 4 hours, followed by methanol fixation, permeabilization, and analysis using a pSTAT-specific antibody. STAT molecules are key drivers of cell signaling upon cytokine activation of cells, with pSTAT5 being particularly important for IL-2 activity. Indeed, we confirmed induction of pSTAT5 upon incubation with IL-2, but not with medium. IL-12, as a control, is not able to induce activation of STAT5, as observed in this experiment. Tpo and eltrombopag specifically showed induction of STAT5 activity, which was most evident in the TpoR.IL2rγ CrGFR, demonstrating that there is clear activation of the correct STAT5 activation pathway when stimulated with eltrombopag.

[0056] conclusion Growth factor receptors that respond to clinically available drugs can be introduced into T cells by gene transfer techniques and maintain the functional ability to deliver cell proliferation / survival signals in T cells. Importantly, we show, as an example, that primary human T cells engrafted with TpoR-based CrGFR respond to the clinically available drug eltrombopag and proliferate and survive in the absence of IL-2, which is normally required for optimal T cell proliferation.

[0057] Here, we tested a number of functional variants based on TpoR fused to a number of costimulatory or co-signaling molecules or signaling domains from other growth factor receptors. We showed that these receptors confer IL-2-independent proliferation and survival in primary human T cells and tumor-infiltrating lymphocytes in the presence of the TpoR agonist eltrombopag. In particular, we found that TpoR.CD40 fusion CrGFR conferred highly specific eltrombopag-mediated TIL survival / proliferation and showed optimal activity in primary human T cells. Aspects and embodiments of the invention are also described in the following sections:

[0058] 1. (i) Extracellular (EC) domain; (ii) the thrombopoietin transmembrane (TM) domain; and (iii) a chimeric growth factor receptor intracellular (IC) domain A T cell or NK cell comprising a chimeric recombinant growth factor receptor (CrGFR). 2. A T cell or NK cell described in item 1, wherein binding of the ligand to the CrGFR induces proliferation of the T cell or NK cell. 3. The T cell or NK cell described in item 2, wherein the ligand is human thrombopoietin, a thrombopoietin receptor agonist, or a tumor-associated antigen. 4. The T cell or NK cell described in item 3, wherein the thrombopoietin receptor agonist binds to the TM domain. 5. The T cell or NK cell according to item 3 or 4, wherein the thrombopoietin receptor agonist is selected from eltrombopag and romiplostim.

[0059] 6. A T cell or NK cell according to any one of items 1 to 5, wherein the EC domain comprises a human c-mpl EC domain. 7. The T cell or NK cell according to items 1 to 6, wherein the EC domain comprises one or more of: i) a truncated EC domain; ii) a truncated c-mpl EC domain; iii) a domain that binds to a tumor-associated antigen; iv) an antibody or antibody fragment that binds to a tumor-associated antigen; and v) a selection marker. 8. The T cell or NK cell according to items 1 to 7, wherein the IC domain comprises a costimulatory, co-inhibitory or co-signaling domain derived from any costimulatory, co-inhibitory or co-signaling molecule, such as, but not limited to, CD2, CD27, CD28, CD29, CD134, CD137, CD150, PD1, etc. 9. The T cell or NK cell according to items 1 to 8, wherein the first IC domain is selected from human growth hormone receptor, human prolactin receptor, human thrombopoietin receptor (c-mpl), G-CSF receptor or GM-CSF receptor. 10. The T cell or NK cell according to items 1 to 9, wherein the additional IC domain is selected from human growth hormone receptor, human prolactin receptor, human thrombopoietin receptor (c-mpl), G-CSF receptor or GM-CSF receptor, or a costimulatory or co-signaling receptor. In addition, the IC domain also comprises a second domain derived from any of the following (but not limited to): a cytokine receptor signaling domain (e.g., IL2 receptor), a co-signaling domain (e.g., CD40), a viral oncogenic protein (e.g., LMP1), a costimulatory domain (e.g., CD28, CD137, CD150, etc.), or another mitogenic domain (e.g., Toll-like receptor, immunoreceptor tyrosine-based activation motif, CD3 signaling domain, etc.). This second domain is fused directly to the C-terminus or N-terminus of the TpoR IC domain or fused via a linker domain.

[0060] 10. The T cell or NK cell according to items 1 to 9, which has a human thrombopoietin receptor TM domain or a variant thereof having at least 80% sequence identity that binds to human thrombopoietin or a thrombopoietin receptor agonist. 11. A T cell or NK cell according to claims 1 to 10, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 3, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 12. A T cell or NK cell according to claims 1 to 11, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 4, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 13. A T cell or NK cell according to claims 1 to 12, wherein the CrGFR comprises the sequence shown as SEQ ID NO:5, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag.

[0061] 14. A T cell or NK cell according to claims 1 to 13, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 6, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 15. A T cell or NK cell according to claims 1 to 14, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 7, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 16. A T cell or NK cell according to claims 1 to 15, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 8, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 17. A T cell or NK cell according to claims 1 to 16, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 9, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag.

[0062] 18. A T cell or NK cell according to claims 1 to 17, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 10, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 19. A T cell or NK cell according to claims 1 to 18, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 11, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 20. A T cell or NK cell according to claims 1 to 19, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 12, or a variant thereof having at least 80% sequence identity at the protein level, or comprising a TpoR IC domain truncated at the C-terminus by up to 79 amino acids, or comprising an alternative EC domain which maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 21. A T cell or NK cell according to claims 1 to 20, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 13, or a variant thereof having at least 80% sequence identity at the protein level, or comprising an alternative EC domain that maintains the ability to respond to synthetic agonist drugs, such as eltrombopag.

[0063] 22. A T cell or NK cell according to claims 1 to 21, wherein the CrGFR comprises the sequence shown as SEQ ID NO: 14, or a variant thereof having at least 80% sequence identity at the protein level, or comprising an alternative EC domain that maintains the ability to respond to synthetic agonist drugs, such as eltrombopag. 23. A T cell or NK cell described in claims 1 to 22, including a variant thereof in which the CrGFR has a sequence as set forth in any of SEQ ID NOs: 3 to 14, or has at least 80% sequence identity, but which i) retains the ability to bind to human thrombopoietin or a human thrombopoietin receptor agonist; and ii) induces cell proliferation or survival. 24. A T cell or NK cell according to any one of items 1 to 23, which binds to eltrombopag. 25. The T cell or NK cell according to any one of items 1 to 24, wherein the T cell is selected from a tumor infiltrating lymphocyte (TIL), a regulatory T cell (Treg) or a primary T cell.

[0064] 26. A T cell or NK cell according to any one of items 1 to 25, further comprising a recombinant T cell receptor (TCR) and / or a chimeric antigen receptor (CAR). 27. A nucleic acid sequence encoding a CrGFR as defined in any one of claims 1 to 26. 28. The nucleic acid sequence according to item 27, comprising the sequences set forth as SEQ ID NOs: 17 to 28, or variants thereof that do not change the translated protein sequence. 29. The nucleic acid sequence according to item 27, comprising the sequence as set forth in SEQ ID NO: 3 to 12, but including the IC domain as set forth in SEQ ID NO: 2. 30. A vector comprising the nucleic acid sequence according to items 27 to 29, or any variant thereof that does not alter the translated protein sequence.

[0065] 31. A method for producing a T cell or a NK cell according to any one of items 1 to 26, comprising a step of introducing a nucleic acid sequence according to items 27 to 29, or a vector according to items 19 to 28 into a T cell or a NK cell. 32. A pharmaceutical composition comprising the vector according to item 30, or the T cell or NK cell according to items 1 to 26, together with a pharma- ceutically acceptable carrier, diluent or excipient. 33. A method for in vivo cell proliferation, comprising administering to a subject the cell of any one of items 1 to 26 or the pharmaceutical composition of item 32. 34. The method for expanding cells in vivo according to item 33, comprising administering thrombopoietin or a thrombopoietin receptor agonist, such as eltrombopag or romiplostim, to a subject. 35. A T cell or NK cell according to any of items 1 to 26, or a vector according to item 30, for use in adoptive cell therapy.

[0066] 36. The T cell or NK cell according to any one of items 1 to 26, or the vector according to item 30, for use in a method for treating cancer. 37. A method for treating cancer, comprising the step of administering the T cell or NK cell according to any one of items 1 to 26 to a subject. 38. Use of the vector according to item 30, or the T cell or NK cell according to any of items 1 to 26, in the manufacture of a medicament for treating cancer. 39. Eltrombopag for use in adoptive cellular therapy. 40. Eltrombopag for use in the in vitro or in vivo expansion of T cells or NK cells according to any of items 1 to 26. 41. A composition comprising the T cells or NK cells according to items 1 to 26 for use in combination with thrombopoietin or a thrombopoietin receptor agonist in the treatment of cancer.

[0067] JPEG2024156656000002.jpg107170 JPEG2024156656000003.jpg216170 JPEG2024156656000004.jpg170170 array In the amino acid sequences below, bold indicates sequences derived from TpoR. [Table 1] ** indicates a stop codon The transmembrane domains are underlined (SEQ ID NOs: 1 to 15).

[0068] SEQ ID NO:1: Wild-type TpoR The 635 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, and 514–635 (bold, italic): TpoR cytoplasmic domain.

[0069] [ka] SEQ ID NO: 15: Wild-type TpoR [ka] SEQ ID NO: 2: TpoR.Δ60 The 580 amino acids are shown from the N-terminus to the C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, and 514–580 (bold, italic): C-terminally truncated TpoR cytoplasmic domain. [ka] SEQ ID NO: 16: TpoR.Δ60 [ka] SEQ ID NO: 3: TpoR.TpoR-cyt.IL2rβ-cyt The 626 amino acids are shown from N- to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–538 (bold, italic): C-terminally truncated TpoR cytoplasmic domain, and 539–626 (unformatted): IL2rβ cytoplasmic domain.

[0070] [ka] SEQ ID NO: 17: TpoR.TpoR-cyt.IL2rβ-cyt [ka] SEQ ID NO: 4: TpoR.IL2rB-cyt.TpoR-cyt The 808 amino acids are shown from N- to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–709 (unformatted): IL2rB cytoplasmic domain, and 710–808 (bold, italic): N-terminally truncated TpoR cytoplasmic domain.

[0071] [ka] SEQ ID NO: 18: TpoR.IL2rB-cyt.TpoR-cyt [ka] SEQ ID NO: 5: TpoR.SLAM The 710 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–710 (unformatted): SLAM cytoplasmic domain.

[0072] [ka] SEQ ID NO: 19: TpoR.SLAM [ka] SEQ ID NO: 6: TpoR.IL2rγ The 721 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–721 (unformatted): IL2rγ cytoplasmic domain. [ka] SEQ ID NO: 20: TpoR.IL2rγ

[0073] [ka] SEQ ID NO: 7: TpoR-TLR1 The 817 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–817 (unformatted): TLR1 cytoplasmic domain. [ka] SEQ ID NO: 21: TpoR-TLR1 [ka] SEQ ID NO: 8: TpoR-TIAF1 The 750 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–750 (unformatted): TIAF1 cytoplasmic domain.

[0074] [ka] SEQ ID NO: 22: TpoR-TIAF1 [ka] SEQ ID NO: 9: TpoR-CD40 The 697 amino acids are listed from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–697 (unformatted): CD40 cytoplasmic domain. [ka] SEQ ID NO: 23: TpoR-CD40

[0075] [ka] SEQ ID NO: 10: TpoR-ITAM1 The 676 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–676 (unformatted): ITAM1 cytoplasmic domain. [ka] SEQ ID NO: 24: TpoR-ITAM1

[0076] [ka] SEQ ID NO: 11: TpoR.TpoR-cyt.LMP1-cyt The 836 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–635 (bold, italic): TpoR cytoplasmic domain, and 636–836 (unformatted): LMP-1 cytoplasmic domain. [ka] SEQ ID NO: 25: TpoR.TpoR-cyt.LMP1-cyt

[0077] [ka] SEQ ID NO: 12: TpoR.LMP1-cyt The 714 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, and 514–714 (unformatted): LMP-1 cytoplasmic domain. [ka] SEQ ID NO: 26: TpoR.LMP1-cyt

[0078] [ka] SEQ ID NO: 13: TpoRec.TpoRtm.CD137cyto 555 amino acids are shown from N-terminus to C-terminus, of which 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, and 514–555 (unformatted): CD137 cytoplasmic domain. [ka] SEQ ID NO: 27: TpoRec.TpoRtm.CD137cyto

[0079] [ka] SEQ ID NO: 14: TpoRec.TpoRtm.CD28cyto 554 amino acids are shown from N-terminus to C-terminus: 1–491 (bold): TpoR extracellular domain, 492–513 (bold, underlined): TpoR TM domain, 514–554 (unformatted): CD28 cytoplasmic domain. [ka] SEQ ID NO: 28: TpoRec.TpoRtm.CD28cyto [ka]

Claims

1. (i) the extracellular (EC) domain; (ii) the thrombopoietin transmembrane (TM) domain; and (iii) a first intracellular (IC) domain; and optionally, (iv) a second intracellular domain. A T cell or NK cell comprising a chimeric recombinant growth factor receptor (CrGFR) comprising:

2. The T cell or NK cell of claim 1 , wherein binding of a ligand to CrGFR induces proliferation of the T cell or NK cell.

3. The T cell or NK cell of claim 2 , wherein the ligand is human thrombopoietin, a thrombopoietin receptor agonist, or a tumor-associated antigen.

4. The T cell or NK cell of claim 3 , wherein the thrombopoietin receptor agonist binds to the TM domain.

5. 5. The T cell or NK cell of claim 3 or claim 4, wherein the thrombopoietin receptor agonist is selected from eltrombopag and romiplostim.

6. The T cell or NK cell according to any one of claims 1 to 5, wherein the EC domain comprises a human c-mpl (thrombopoietin) EC domain.

7. 6. The T or NK cell of any one of claims 1 to 5, wherein the EC domain comprises one or more of: i) a truncated EC domain, ii) a truncated c-mpl EC domain, iii) a domain that binds to a tumor-associated antigen, iv) an antibody or antibody fragment that binds to a tumor-associated antigen; and v) a selection marker.

8. 8. The T cell or NK cell of any one of claims 1 to 7, wherein the first IC domain is selected from human growth hormone receptor, human prolactin receptor, human thrombopoietin receptor (c-mpl), G-CSF receptor, GM-CSF receptor, LMP, IL2, CD28 or CD137.

9. The T cell or NK cell of any one of claims 1 to 8, wherein the first IC domain comprises an IC domain derived from the human thrombopoietin receptor (c-mpl) or a truncated IC domain derived from the human thrombopoietin receptor (c-mpl).

10. 10. The T or NK cell of any one of claims 1 to 9, wherein the second IC domain is derived from a human growth hormone receptor, a human prolactin receptor, a human thrombopoietin receptor (c-mpl), a G-CSF receptor or a GM-CSF receptor, a costimulatory receptor, a cytokine receptor or a co-signaling receptor.

11. 10. The T or NK cell of claim 8 or claim 9, wherein the second IC domain is selected from the human thrombopoietin receptor (c-mpl), or a truncated IC domain derived from the human thrombopoietin receptor (c-mpl), preferably TpoRΔ60, CD40, IL2rβ, IL2Rγ, ITAM1 or LMP1.

12. 12. The T or NK cell of any one of claims 1 to 11, wherein the CrGFR comprises the TM sequence shown in SEQ ID NO: 1, or a variant thereof having at least 80% sequence identity that binds to human thrombopoietin or a thrombopoietin receptor agonist.

13. A T cell or NK cell comprising a chimeric recombinant growth factor receptor (CrGFR) comprising a sequence set forth as SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or a variant thereof having at least 80%, 85%, 90%, 95%, 97% or 99% sequence identity that binds to human thrombopoietin or a thrombopoietin receptor agonist.

14. The T cell or NK cell of claim 13, wherein binding by thrombopoietin or a human thrombopoietin receptor agonist induces cell proliferation and / or survival.

15. The T cell or NK cell of any one of claims 1 to 14, which binds to eltrombopag.

16. The T cell or NK cell of any one of claims 1 to 15, wherein the T cell is selected from a tumor infiltrating lymphocyte (TIL), a regulatory T cell (Treg) or a primary T cell.

17. The T or NK cell of any one of claims 1 to 16, further comprising a recombinant T cell receptor (TCR) and / or a chimeric antigen receptor (CAR).

18. A chimeric recombinant growth factor receptor (CrGFR) as defined in any one of claims 1 to 17.

19. A cell comprising the chimeric recombinant growth factor receptor (CrGFR) of claim 18.

20. A nucleic acid sequence encoding CrGFR as defined in any one of claims 1 to 19.

21. 21. The nucleic acid sequence of claim 20 comprising the sequence set forth as SEQ ID NO: 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28.

22. A vector comprising the nucleic acid sequence of claim 20 or 21.

23. A method for producing a T cell or NK cell according to any one of claims 1 to 17, comprising the step of introducing a nucleic acid according to claim 20 or 21, or a vector according to claim 22, into a T cell or NK cell.

24. A pharmaceutical composition comprising a vector according to claim 22, or a T cell or NK cell according to claims 1 to 17, together with a pharma- ceutically acceptable carrier, diluent or excipient.

25. A method for in vivo cell proliferation, comprising administering to a subject the cell of any one of claims 1 to 17 or the pharmaceutical composition of claim 24.

26. 26. The method of expanding cells in vivo according to claim 25, comprising administering to a subject thrombopoietin or a thrombopoietin receptor agonist, such as eltrombopag or romiplostim.

27. A T cell or NK cell according to any one of claims 1 to 17, or a vector according to claim 22, for use in adoptive cell therapy.

28. A T cell or NK cell according to any one of claims 1 to 17, or a vector according to claim 22, for use in a method of treating cancer.

29. A method for treating cancer, comprising the step of administering to a subject the T cell or NK cell of any one of claims 1 to 17.

30. Use of a vector according to claim 22, or a T cell or NK cell according to any one of claims 1 to 17, in the manufacture of a medicament for treating cancer.

31. Eltrombopag for use in the in vitro or in vivo expansion of T cells or NK cells according to any one of claims 1 to 17.

32. A composition comprising the T cells or NK cells of claims 1 to 17 for use in combination with thrombopoietin or a thrombopoietin receptor agonist in the treatment of cancer.